Our study of global transcriptome alterations in response to Erk1/2i + CDK4/6i treatment in MM cells, with or without Erk1/2 knockdown, identified gene-sets that were commonly and persistently downregulated in cells treated with Erk1/2i + CDK4/6i. This evidence concerns the gene CDK4 and Miyoshi myopathy.